However, the lack of Intellectual Property recognition for several biologics, that prompted Novartis's shift of R+D investment from India to China, is a concern for the innovative industry. - The large market shares of generics in the Emerging markets have resulted in numerous generic supply deals by companies including Pfizer, GSK, Sanofi Aventis, Novartis, Daiichi Sankyo and Abbott.